2.2.0.25truefalse4120 - Disclosure - Acquisition of ViroChem Pharma Inc. (Details)truefalsefalse1falsefalseUSDfalsefalse3/31/2011 USD ($) USD ($) / shares $I2011Q1http://www.sec.gov/CIK0000875320instant2011-03-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2010 USD ($) USD ($) / shares $I2010http://www.sec.gov/CIK0000875320instant2010-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalsetruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. 3/1/2009 - 3/31/2009 D2009Q3_M03_ViroChemPharmaMemberhttp://www.sec.gov/CIK0000875320duration2009-03-01T00:00:002009-03-31T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli04falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. 3/31/2011 USD ($) $I2011Q1_ViroChemPharmaMemberhttp://www.sec.gov/CIK0000875320instant2011-03-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. 12/31/2010 USD ($) $I2010_ViroChemPharmaMemberhttp://www.sec.gov/CIK0000875320instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. 3/12/2009 USD ($) $I2009Q1_M0312_ViroChemPharmaMemberhttp://www.sec.gov/CIK0000875320instant2009-03-12T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. {us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : VX-222 3/31/2011 USD ($) $I2011Q1_ViroChemPharmaMember_VX222Memberhttp://www.sec.gov/CIK0000875320instant2011-03-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseVX-222us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_VX222Memberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. {us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : VX-222 12/31/2010 USD ($) $I2010_ViroChemPharmaMember_VX222Memberhttp://www.sec.gov/CIK0000875320instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseVX-222us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_VX222Memberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. {us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : VX-759 3/31/2011 USD ($) $I2011Q1_ViroChemPharmaMember_VX759Memberhttp://www.sec.gov/CIK0000875320instant2011-03-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseVX-759us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_VX759Memberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : ViroChem Pharma Inc. {us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis} : VX-759 12/31/2010 USD ($) $I2010_ViroChemPharmaMember_VX759Memberhttp://www.sec.gov/CIK0000875320instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseViroChem Pharma Inc.us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_ViroChemPharmaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseVX-759us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldivrtx_VX759Memberus-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2true0us-gaap_BusinessAcquisitionLineItemsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.falsefalseBusiness Acquisition3false0us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsetruefalse4falsetruefalse00falsefalsefalsetruefalse5falsetruefalse00falsefalsefalsetruefalse6truetruefalse1.001.00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepurePercentage of voting equity interests acquired in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph c falsefalsePercent of voting interest acquired in ViroChem (as a percent)4false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIssuedus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse1073352710733527falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerNumber of shares of equity interests issued or issuable to acquire entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d falsefalsePortion of purchase price paid in common shares for the acquisition of ViroChem (in shares)5false0vrtx_BusinessAcquisitionNumberOfClinicalDevelopmentStageDrugsAcquiredvrtxfalsenadurationThe number of clinical-development stage drugs that were added to the entity's portfolio.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse22falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerThe number of clinical-development stage drugs that were added to the entity's portfolio.No authoritative reference available.falsefalseNumber of clinical-development stage HCV drugs added to drug development portfolio6true0us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePriceAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringNo definition available.falsefalseAcquisition-date fair value of the consideration7false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse100000000100000000falsetruefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 68 -Subparagraph f(1) Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d falsefalseCash8false0us-gaap_OtherIndefiniteLivedIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse518700000518700000falsefalsefalsefalsefalse2truefalsefalse518700000518700000falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse412900000412900000falsefalsefalsetruefalse8truefalsefalse412900000412900000falsefalsefalsetruefalse9truefalsefalse105800000105800000falsefalsefalsetruefalse10truefalsefalse105800000105800000falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryCarrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights not otherwise specified in the taxonomy having a projected indefinite period of benefit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph b falsefalseIntangible assets9false0us-gaap_DeferredTaxLiabilitiesNoncurrentus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse160278000160278000falsetruefalsefalsefalse2truefalsefalse160278000160278000falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4truefalsefalse160300000160300000falsetruefalsetruefalse5truefalsefalse160300000160300000falsetruefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryRepresents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42 falsefalseDeferred tax liability108Acquisition of ViroChem Pharma Inc. (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruetrue